모든 카테고리
| Product Name | 기술 | Action |
|---|---|---|
| 아미반타맙, 리브레반트, EGFR, cMet (MET), JNJ-61186372, EGFR/c-MET 이중특이항체, 완전 인간 IgG1 이중특이항체, 종양 면역요법 / 비소세포폐암 생물학적 제제, CAS No.2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotin | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 오비누투즈마브,가지바,CD20,GA101,CAS 번호 949142-50-1,Anti-CD20 단일 클론 항체 (형 II),인유화된 글리코 엔지니어링 IgG1 항체,종양학 생물학 / CLL 생물학 / 엽서 림프종 생물학 | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 이보네시마브, YIDAFANG® ((중국에서 사용 허가된 상표 이름), AK112, PD-1/VEGF 비스페시픽 항체, 암 치료 면역 치료 / 항혈관 생성 치료, PD-1/VEGF 비스페시픽 항체, CAS 번호2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| 다토포타맙 데룩스테칸-dlnk | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| テネクテプラーゼ | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 타를라타맙, 임델트라, DLL3&CD3, AMG 757, 종양학 면역요법 / SCLC 생물학 제제, 정맥 주입, T세포 매개 세포 독성, 이중 특이성 T세포 이중 특이성, CAS 번호 2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| 세르플루리마브, 한시추앙, PD-1, 헤트로니플라이, HLX10, 안티-PD-1 면역 체크포인트 억제, 인간화 된 IgG4 단일 클론 항체, 단일 클론 항체, CAS 번호 2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
